The COVID-19 pandemic has disrupted healthcare and many parts of the U.S. economy, but employer-based health insurance?
The COVID-19 pandemic has disrupted healthcare and many parts of the U.S. economy, but employer-based health insurance? Largely unruffled, according to results of the Kaiser Family Foundation’s annual survey of employer health benefits.
The average annual premium for single and family coverage increased by 4% from 2020 to 2021, the same percentage increase as the year before, according to the survey. Covered workers shouldered 17% of the premium for single coverage and 28% for family coverage, similar to the worker share in 2020. The steadiness of the increase does not negate how fast premiums have risen: According to Kaiser, the average premium for family coverage has gone up 22% since 2016, twice the rate of inflation during that period.
The proportion of employers who offered coverage (59%) and the proportion of employees who enrolled in plans offered by their employers (62%) also saw little change between 2020 and 2021.
The broad outlines of the survey may suggest the gelling of a status quo for employer-based health benefits, but that does not mean there haven’t been notable shifts and adjustments. For example, the Kaiser survey found that the proportion of large firms offering biometric screening — checks of cholesterol levels, blood pressure and body mass index — is decreasing, from 50% in 2020 to 38% in 2021.
Wellness programs have, not surprisingly, gone digital and remote. The survey respondents indicated that 21% of the programs added a digital offering in 2021 and 34% reported tweaking their programs to accommodate people working at home.
And, of course, telemedicine is ascendant. Nearly all (95%) of the employers with 50 or more employees offered telemedicine in 2021, which the Kaiser survey defined as telecommunications with a provider in a different location (email and web-based videos did not count). That’s up from 85% in 2020.
The survey also revealed an interesting swing to “level-funded” plans among small employers that are self-insured. As explained by the Kaiser researchers who conducted the survey, level-funded plans bundled self-funding with extensive stop-loss insurance. The companies that sell the coverage charge a monthly fee (as the Kaiser researchers point out, it resembles a premium) that includes a percentage of the expected cost of the provision of the healthcare benefits, a premium for stop-loss coverage and an administrative fee.
The plan administrator, often an insurer, can consider the health status of the workforce, so level-funding can be a good deal for companies with employees who are young and, on average, healthy. But level-funding, because it is a form of self-insurance, escapes state premium taxes and state-mandated benefits. The Kaiser researchers reported that the survey showed a steep increase in the share of small firms with level-funded plans, from 13% in 2020 to 42% in 2021.
The Kaiser survey was conducted from mid-January 2021 through July. Representatives of 1,686 firms filled out the survey. Kaiser researchers reported the findings in Health Affairs in November.
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More